

PROVENGE[®] (sipuleucel-T) is and will continue to be available for patients

PROVENGE is and will continue to be available for patients

- We are taking the steps necessary to ensure that our customer programs and agreements will continue uninterrupted through this process.
- This includes Dendreon On Call and Dendreon's best-in-class patient access and assistance programs, which are available and open.
- We fully expect to service distributors and wholesalers to ensure timely fulfillment of orders and shipments and to meet other obligations to physicians and patients who depend on PROVENGE.
- Our primary focus continues to be on executing on our mission to serve our physician customers and your patients with excellence.

Will Dendreon still be able to meet the needs of patients and providers?

- The restructuring process is expected to have no impact on our operations.
- Dendreon has significant liquidity to support its operations throughout the financial restructuring process and does not anticipate the need to raise any incremental financing during the restructuring process.

Dendreon to continue operating in the ordinary course

- Dendreon has reached agreements with certain of its senior noteholders (lenders) on the terms of a financial restructuring.
- The agreements will enable continued delivery of PROVENGE without disruption or impact to access for providers and appropriate patients in need of this revolutionary personalized immunotherapy treatment.
- Under the terms of the agreements, the financial restructuring may take the form of a stand-alone reorganization or a sale of Dendreon to a party that would continue producing and providing PROVENGE.
- To implement the terms of the agreements, Dendreon and its U.S. subsidiaries have filed for voluntary reorganization under Chapter 11 of the Bankruptcy Code in Wilmington, DE.

Does this Financial Restructuring mean that Dendreon will go out of business?

- No Dendreon's operations will continue in the ordinary course and PROVENGE will remain available.
- This is a financial restructuring process and is NOT a liquidation of the business.
- Many other companies have successfully gone through Chapter 11 and emerged in strong positions such as General Motors, Delta Airlines or, in the pharmaceutical industry, K-V Pharmaceutical.
- If you have additional questions, please do not hesitate to contact your regular Dendreon representative.
- Additional information about the restructuring process, court documents and other information is available through Dendreon's claims agent at <u>https://cases.primeclerk.com/dendreon</u> or 844-794-3479.